Explore 3 Stock Ideas & Industry Insights Download Free Report

800-234-336
Shopping Cart 0
countryflagNZ
Login

Carl Zeiss Meditec AG ADR

Healthcare US CZMWY

30.36USD
0.05(0.17%)

Last update at 2026-06-03T20:00:00Z

Day Range

29.9730.31
LowHigh

52 Week Range

26.4071.86
LowHigh

Fundamentals

  • Previous Close 30.31
  • Market Cap2872.93M
  • Volume2341
  • P/E Ratio17.37
  • Dividend Yield1.92%
  • EBITDA248.64M
  • Revenue TTM2204.14M
  • Revenue Per Share TTM25.59
  • Gross Profit TTM 1150.30M
  • Diluted EPS TTM1.89

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Analyst Recommendations

Financials

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2025-09-30 2024-09-30 2023-09-30 2022-09-30 2021-09-30
Type yearly yearly yearly yearly yearly
Date 2025-09-30 2024-09-30 2023-09-30 2022-09-30 2021-09-30
Income before tax 193.89M 240.87M 412.56M 403.49M 339.05M
Minority interest -1.13500M -1.42800M -1.61300M -2.00200M -1.24300M
Net income 141.21M 178.73M 290.40M 293.91M 236.28M
Selling general administrative 131.42M 111.01M 83.78M 77.88M 60.75M
Selling and marketing expenses 495.10M 458.20M 420.28M 360.18M 303.23M
Gross profit 1175.20M 1088.63M 1205.77M 1127.60M 967.21M
Reconciled depreciation 126.38M 132.77M 74.06M 69.77M 61.58M
Ebit 220.52M 187.41M 427.81M 413.08M 348.42M
Ebitda 346.89M 225.05M 501.88M 482.85M 410.00M
Depreciation and amortization 126.38M 37.64M 74.06M 69.77M 61.58M
Non operating income net other - - - - -
Operating income 223.32M 121.35M 427.81M 413.08M 348.42M
Other operating expenses 2004.33M 1944.78M 1741.18M 1505.96M 1273.17M
Interest expense 29.37M 31.89M 15.25M 9.59M 9.37M
Tax provision 51.55M 60.71M 120.56M 107.58M 101.53M
Interest income 6.57M 23.27M 29.05M 13.25M 1.56M
Net interest income -18.99500M 37.85M 27.13M 55.24M -9.46000M
Extraordinary items - - - - -
Non recurring - - - - -
Other items - - - - -
Income tax expense 48.59M 60.71M 120.56M 107.58M 101.53M
Total revenue 2227.64M 2066.13M 2089.30M 1902.84M 1646.79M
Total operating expenses 951.88M 967.28M 857.64M 730.72M 593.60M
Cost of revenue 1052.45M 977.50M 883.53M 775.24M 679.57M
Total other income expense net -29.42800M 119.52M -15.25000M -9.59300M -9.36500M
Discontinued operations - - - - -
Net income from continuing ops 142.34M 180.15M 292.01M 295.91M 237.52M
Net income applicable to common shares - - - 293.91M 236.28M
Preferred stock and other adjustments - - - - -
Breakdown 2025-09-30 2024-09-30 2023-09-30 2022-09-30 2021-09-30
Type yearly yearly yearly yearly yearly
Date 2025-09-30 2024-09-30 2023-09-30 2022-09-30 2021-09-30
Total assets 4064.84M 3393.20M 3032.92M 2822.82M 2395.97M
Intangible assets 778.88M 706.85M 259.49M 240.43M 153.70M
Earning assets - - - - -
Other current assets 167.37M 72.85M - 23.66M 1310.20M
Total liab 1564.79M 1336.72M 860.02M 792.73M 718.59M
Total stockholder equity 2486.89M 2041.70M 2159.45M 2015.10M 1659.33M
Deferred long term liab - - - 224.83M 137.12M
Other current liab 318.86M 324.88M 300.04M 328.54M 2.89M
Common stock 105.09M 89.44M 89.44M 89.44M 89.44M
Capital stock 89.44M 89.44M 89.44M 89.44M 89.44M
Retained earnings 1850.76M 1486.42M 1405.90M 1213.89M 1000.48M
Other liab - - - 147.09M 168.54M
Good will 1139.44M 982.50M 415.78M 429.65M 328.71M
Other assets - - - 373.59M 262.56M
Cash 27.27M 20.29M 10.60M 7.73M 7.44M
Cash and equivalents - - - - -
Total current liabilities 543.81M 568.84M 561.65M 539.32M 448.12M
Current deferred revenue - - 294.47M - 280.43M
Net debt 105.19M 133.54M 145.09M 120.17M 113.83M
Short term debt 67.97M 27.07M 21.82M 21.59M 19.34M
Short long term debt - - - - -
Short long term debt total 132.46M 153.83M 155.70M 127.90M 121.27M
Other stockholder equity 552.32M 470.06M 664.11M 711.77M 569.41M
Property plant equipment - - - 201.30M 177.39M
Total current assets 1504.35M 1212.48M 1911.73M 1791.85M 1604.02M
Long term investments - - - - -
Net tangible assets - - - 1569.86M 1314.04M
Short term investments - - - - -17.52100M
Net receivables 812.73M 583.18M 196.92M 1365.27M 1293.70M
Long term debt - - - - -
Inventory 496.98M 536.16M 520.23M 382.75M 286.38M
Accounts payable 127.99M 183.54M 239.79M 189.19M 145.47M
Total permanent equity - - - - -
Noncontrolling interest in consolidated entity - - - - -
Temporary equity redeemable noncontrolling interests - - - - -
Accumulated other comprehensive income -21.27690M -4.22900M - - -
Additional paid in capital - - - - -
Common stock total equity - - - - -
Preferred stock total equity - - - - -
Retained earnings total equity - - - - -
Treasury stock - - - - -
Accumulated amortization - - - - -
Non currrent assets other 159.98M 30.90M 66.45M 52.99M 0.79M
Deferred long term asset charges - - - - -
Non current assets total 2560.49M 2180.72M 1121.20M 1030.96M 791.95M
Capital lease obligations 132.46M 151.35M 155.70M 127.90M 121.27M
Long term debt total - - - - -
Breakdown 2025-09-30 2024-09-30 2023-09-30 2022-09-30 2021-09-30
Type yearly yearly yearly yearly yearly
Date 2025-09-30 2024-09-30 2023-09-30 2022-09-30 2021-09-30
Investments -25.65300M -412.30500M -110.98000M -67.14100M -13.92500M
Change to liabilities - - - 33.73M 52.69M
Total cashflows from investing activities -100.49317M -412.30500M - -148.89400M -75.20000M
Net borrowings 0.07M 400.21M - -21.95700M -17.30700M
Total cash from financing activities -120.14425M 176.25M -135.09400M -38.23600M -285.88900M
Change to operating activities - - - 5.76M 61.04M
Net income 142.34M 180.15M 292.01M 295.91M 237.52M
Change in cash 9.40M 9.68M 2.87M 0.29M 1.24M
Begin period cash flow 22.64M 10.60M 7.73M 7.44M 6.20M
End period cash flow 32.04M 20.29M 10.60M 7.73M 7.44M
Total cash from operating activities 231.68M 247.32M 250.86M 188.20M 362.66M
Issuance of capital stock - - - - -
Depreciation 126.38M 132.77M 74.06M 69.77M 61.58M
Other cashflows from investing activities -32.97717M -65.32400M - - -
Dividends paid 57.98M 98.20M 98.39M 80.50M 44.72M
Change to inventory 26.60M 24.38M -152.60400M -74.63100M 0.02M
Change to account receivables -106.47900M 21.62M - -74.37000M -62.10200M
Sale purchase of stock 0.00000M -150.07500M - - -
Other cashflows from financing activities -62.23540M 24.32M -36.70900M 42.26M -241.16900M
Change to netincome - - - -65.96900M 13.16M
Capital expenditures 43.49M 152.20M 113.86M 81.97M 66.10M
Change receivables - - - - -
Cash flows other operating - - - - -
Exchange rate changes - - - - -
Cash and cash equivalents changes - - - - -
Change in working capital -36.66600M 15.10M -125.87900M -109.51000M 51.65M
Stock based compensation - - - - -
Other non cash items -0.37523M -80.71000M 10.67M -67.97100M 11.91M
Free cash flow 188.19M 95.11M 137.00M 106.23M 296.56M

Peer Comparison

Sector: Healthcare Industry: Medical Instruments & Supplies

Company Change (USD) Price (USD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to Revenue (x) Enterprise Value to EBITDA (x)
CZMWY
Carl Zeiss Meditec AG ADR		 0.05 0.17% 30.36 17.37 19.19 1.30 1.15 1.14 7.35
ISRG
Intuitive Surgical Inc		 7.86 1.93% 415.15 73.05 61.73 19.15 10.25 18.41 59.92
ESLOF
EssilorLuxottica Société anonyme		 - -% 201.48 44.84 27.62 4.07 2.49 3.71 16.04
ESLOY
Essilor International SA		 3.96 4.03% 102.13 41.68 27.25 3.94 2.45 3.71 16.04
BDX
Becton Dickinson and Company		 3.38 2.32% 148.99 25.56 12.48 2.59 1.76 2.89 12.55

Reports Covered

Stock Research & News

View All

Profile

Carl Zeiss Meditec AG operates as a medical technology company in Germany, rest of Europe, North America, and Asia. It operates in two segments, Ophthalmology and Microsurgery. The Ophthalmology segment offers products and solutions for the diagnosis and treatment of chronic eye diseases, including slit lamps, refractometers, and tonometers; optical coherence tomography and fundus cameras for retina examination; functional glaucoma diagnostic devices (perimeters); surgical ophthalmology products comprising surgical microscopes, biometers, and phacoemulsification and vitrectomy equipment; intraocular lenses for cataract surgery; and systems and consumables for laser eye surgery that include the VISUMAX femtosecond laser, which enables minimally invasive correction of vision defects using lenticular extraction, as well as digital products for the storage, analysis, and sharing of clinical data. The Microsurgery segment provides products and solutions for minimally invasive surgical treatments, including surgical visualization, interoperative radiotherapy, interoperative pathology, special surgical instruments, and digital solutions, as well as the ZEISS Tumor Workflow, a cross-product workflow solution. It serves physicians in various fields and hospitals. The company was founded in 1846 and is headquartered in Jena, Germany. Carl Zeiss Meditec AG operates as a subsidiary of ZEISS Group.

Carl Zeiss Meditec AG ADR

Göschwitzer Straße 51-52, Jena, Germany, 07745

Key Executives

Name Title Year Born
Mr. Justus Felix Wehmer CFO & Member of the Management Board 1965
Dr. Markus Weber Pres, CEO & Chairman of Management Board NA
Mr. Sebastian Frericks Director of Investor Relations NA
Mr. Martin Wiechmann Head of the Planetarium Bus. Unit NA
Mr. Mike Wang Head of Marketing - Shanghai NA
Mr. Steven C. Schallhorn M.D. Chief Medical Officer for Global Ophthalmic Devices NA
Mr. Andrew Chang Head of Sales for Ophthalmic Devices & Pres of Carl Zeiss Meditec, Inc. NA
Laurie Ferguson Head of Global Communications Ophthalmic Devices NA
Dr. Euan S. Thomson Ph.D. Pres of Ophthalmic Devices & Head of the Ophthalmic Devices Strategic Bus. Unit 1963
Dr. Christian Munster Head of Global Regulatory & Clinical Affairs, CoCe Site Jena & Emp. Rep. Member of Supervisory Board 1971

Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.